ABLYNX (ABLX)

GHENT, Belgium, 28 February 2008 - Ablynx [Euronext Brussels: ABLX],
a pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, announced today its
results for 2007. These are the Company's first set of results since
its successful IPO and listing on Euronext Brussels in November 2007.

2007 Highlights

* Raised a total of ?85.2 million from its IPO on Euronext Brussels
* ?126.5 million in cash at year end
* 150% increase in revenues to ?9.9 million (2006: ?4.0 million)
* ALX-0081, an anti-thrombotic, entered Phase I clinical trials in
April and positive final results were reported in December
* A research and licensing deal worth up to ?1.3 billion was signed
with Boehringer Ingelheim in September 2007
* A collaborative agreement with Boehringer Ingelheim in the area
of Alzheimer's disease worth up to ?206 million was announced in
January 2007
* Key Nanobody® related claims of the Hamers-1 patent were
maintained in opposition appeal proceedings in December
* Wyeth confirmed it was extending the research term with Ablynx as
part of its $212 million TNF-alpha licensing agreement in
December
* The drug discovery and development alliance with Novartis was
extended in December for another year
* ?1.9 million grant was approved by the Flemish government in
September to develop new therapeutic applications of Nanobodies®

Prospects for 2008

Based on the positive Phase I data for ALX-0081, Ablynx intends to
submit a regulatory application to carry out its multiple-dose study
directly in the target patient population rather than in healthy
volunteers. The Company aims to start Phase II development of
ALX-0081 by the end of 2008. As part of Ablynx's strategy to exploit
the Nanobody® advantages and to access larger potential markets, it
has initiated a programme to develop a subcutaneous delivery form of
ALX-0081 and plans to file an IND equivalent for this product by the
end of 2008.

During 2008, Ablynx will further develop its own product pipeline by
advancing other Nanobodies® into pre-clinical studies alone or with
partners. The Company intends to initiate 6-8 new research programmes
during the year as well as further developing its own technology
platform and exploiting the key Nanobody® advantages in areas such as
alternative routes of administration.


http://hugin.info/137912/R/1195953/242791.pdf


Copyright © Hugin AS 2008. All rights reserved.